Related Experiment Videos
[Antithrombotic agents and prevention of cerebrovascular accidents]
Insights
Platelet aggregation inhibitors like aspirin are key for preventing secondary arterial embolism strokes. Oral anticoagulation is beneficial for preventing strokes in non-rheumatic atrial fibrillation.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Stroke prevention is a critical therapeutic strategy.
- Platelet aggregation inhibitors are standard for secondary prevention of arterial embolism stroke.
- Oral anticoagulation is established for stroke prevention in non-rheumatic atrial fibrillation.
Purpose of the Study:
- To review current strategies for stroke prevention.
- To discuss the role of antiplatelet agents and oral anticoagulants.
- To highlight the efficacy of different treatments based on stroke type and patient condition.
Main Methods:
- Literature review of studies on stroke prevention.
- Analysis of treatment guidelines for antiplatelet and anticoagulant therapies.
- Comparison of drug efficacy in primary and secondary stroke prevention.
Main Results:
- Aspirin is the primary agent for secondary prevention of arterial embolism stroke.
- Ticlopidine is an alternative when aspirin is contraindicated or ineffective.
- Clopidogrel's efficacy is under investigation.
- Oral anticoagulation (e.g., coumadin) is superior to aspirin for stroke prevention in non-rheumatic atrial fibrillation.
- Antiplatelet treatment has not been proven for primary stroke prevention.
Conclusions:
- Antiplatelet agents are crucial for secondary stroke prevention in arterial embolism.
- Oral anticoagulation is highly effective for stroke prevention in non-rheumatic atrial fibrillation.
- Treatment choice depends on stroke etiology and patient contraindications.
Abstract:
Prevention remains a major therapeutic approach of stroke. Inhibitors of platelet aggregation are the treatment of choice in the secondary prevention of an arterial embolism stroke. Aspirin (200-300 mg/d) is the most commonly used drug, ticlopidine (500 mg/d) is advised if aspirin is contraindicated or if a recurrent stroke of arterial embolism origin occurs in spite of treatment with aspirin. We are waiting with interest for the results of the clinical trial of clopidogrel, a derivative of ticlopidine. Till now, no studies have proved the benefit of antiplatelet treatment in the primary prevention of stroke. In non rheumatic atrial fibrillation, the unanimous results of recent studies confirmed the benefit of oral anticoagulation in the primary and secondary prevention of stroke. Although coumadin is superior to aspirin in non rheumatic atrial fibrillation, aspirin is an efficient alternative when anticoagulation is contraindicated.